Skip to content

Sellas Life Sciences

US · SLS #2687 by market cap Listed 1970
13.66 -1.20 -8.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:58

Valuation each multiple against its own 5-year range

P/B ratio 12.15 Expensive vs history 73rd percentile
5-year average 7.74 · #468 of 514 in Biotechnology
P/E ratio -39.30 Cheap vs history 8th percentile
5-year average -8.20 · forward -62.70
P/S ratio 1,602.33 Expensive vs history 91st percentile
5-year average 346.81 · forward 39.08 · #360 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Sellas Life Sciences (SLS) 2.78B -68.30 21.11 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value10.99 Economic moatNone UncertaintyVery High

Trading 19.6% above Morningstar's fair value estimate.

Fair value

SELLAS Life Sciences Group Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 28% discount to our quantitative fair value estimate of $10.99 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's liquidity increases our valuation estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days ranks in the top 20% compared with peers globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.3%, a core component of profitability, ranks in the bottom 30% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:58:45 · For reference only, not investment advice and not tailored to your situation.

Sellas Life Sciences discussion 0 comments

Add a comment